India Converts Failing Vaccine Plants to Testing Labs
The Indian government has reacted to the enforced closure of three of its oldest vaccine manufacturing plants by launching a plan to convert them to drug testing laboratories.
INDIA-April 8. 2008-Nick Taylor reports for LabTechnologist.com that the BCG Vaccine Laboratory, Pasteur Institute of India and the Central Research Institute were shut down in January after failing to comply with current good manufacturing practices (cGMP). However, they will now receive a new lease of life testing the safety and efficacy of drugs and vaccines produced and sold within the country or exported. In addition to this they will be responsible for detecting counterfeit and spurious batches of drugs. To read more, click here: www.labtechnologist.com//news/ng.asp?n=84492&c=8YMEJy20NE7MmUMHbx1tWw%3D%3D.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
